Ziconotide Polymer Conjugates for Half-Life Extension
Solution Overview
Problem
Therapeutic peptides have a short in vivo half-life, making them impractical for therapeutic administration due to rapid clearance, which limits their effectiveness and duration of action.
Innovation Solution
Conjugation of therapeutic peptides with water-soluble polymers, such as polyethylene glycol (PEG), to enhance stability and prolong their presence in the body, either through stable covalent attachment or releasable linkages, allowing for extended therapeutic activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic peptides are used in their native form, then they display high selectivity and potency, but they have a short in vivo half-life and are rapidly cleared
Solution Approach 1:
The patent applies composite materials by conjugating therapeutic peptides with water-soluble polymers (such as polyethylene glycol, polyoxyethylene, or dextran) to create a hybrid molecule that combines the high selectivity and potency of the peptide with the extended circulation properties of the polymer. This composite structure allows the peptide to maintain its biological activity while the polymer component provides steric protection and reduces renal clearance, thereby extending the in vivo half-life from minutes to hours or days.
Solution Approach 2:
The water-soluble polymer acts as an intermediary between the therapeutic peptide and the biological system. The polymer conjugate serves as a carrier that protects the peptide from rapid clearance by renal filtration and proteolytic degradation, while still allowing the peptide to interact with its target receptor. The polymer-mediated conjugation enables the peptide to achieve both high selectivity (through peptide-receptor binding) and prolonged duration of action (through reduced clearance).
2Duration of action of moving object
If therapeutic peptides are modified to extend half-life, then in vivo duration is improved, but the chemical and structural complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying the molecular weight, composition, and structure of the water-soluble polymer conjugates to optimize the balance between half-life extension and structural complexity. By adjusting parameters such as the degree of polymerization, polymer type (PEG, dextran, etc.), and conjugation site on the peptide, researchers can fine-tune the in vivo half-life without excessive increases in structural complexity. This allows for a graded approach where moderate polymer sizes provide sufficient half-life extension while maintaining relatively simple structures.
Data Source
Figure KISS1.1~KISS1.2
Figure KISS1.3~KISS2.1
Figure KISS2.2~2.3
AI summary
The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
